Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:Doug_Drysdale
|
| gptkbp:country |
gptkb:Canada
|
| gptkbp:focus |
psychedelic therapeutics
|
| gptkbp:foundedYear |
2019
|
| gptkbp:fullName |
gptkb:Cybin_Inc.
|
| gptkbp:headquartersLocation |
gptkb:Toronto,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
CYBN
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NYSE_American
gptkb:NEO_Exchange |
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchInterest |
gptkb:depression
anxiety mental health treatments psychedelic compounds |
| gptkbp:stockSymbol |
gptkb:CYBN
|
| gptkbp:tradedOn |
gptkb:CYBN
|
| gptkbp:website |
https://www.cybin.com/
|
| gptkbp:bfsParent |
gptkb:CFB_Borden
|
| gptkbp:bfsLayer |
6
|